Page 6 - Genfit Company Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genfit company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genfit Company Profile Today - Breaking & Trending Today

Genfit (NASDAQ:GNFT) versus Aura Biosciences (NASDAQ:AURA) Head-To-Head Contrast

Genfit (NASDAQ:GNFT – Get Rating) and Aura Biosciences (NASDAQ:AURA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Analyst Ratings This is a summary of current ratings for […] ....

United States , United Kingdom , Bart Staels , Aura Biosciences Inc , Get Rating , Aura Biosciences , Given Aura Bioscience , Aura Bioscience , Genfit Daily , Nasdaq Gnft , Stock Comparison , Stock Analysis ,

GENFIT S.A.: GENFIT Reports First Quarter 2023 Financial Information

Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq ....

United States , France General , United Kingdom , Exchange Commission , Uncertainties Of The Company , Transition Services Agreement , Purchase Agreement , Primary Biliary , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Registration Document , Gefallene Big Techs ,

GENFIT Reports First Quarter 2023 Financial Information

Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille ; Cambridge, ; Zurich ; May 11, 2023 - GENFIT , a late-stage biopharmaceutical company. | May 11, 2023 ....

France General , United States , United Kingdom , Uncertainties Of The Company , Transition Services Agreement , Exchange Commission , Purchase Agreement , Primary Biliary , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Registration Document , Genfit Stock Exchange , Press Release , Iopharmaceutical Gnft Fr0004163111 ,

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

Lille ; Cambridge ; Zurich ; May 9, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is. | May 9, 2023 ....

United States , France General , United Kingdom , Stephanie Boyer , Carol Addy , Program At Digestive Disease Week , Exchange Commission , American Gastroenterological Association , Uncertainties Of The Company , American Society For Gastrointestinal Endoscopy , Society For Surgery Of The Alimentary Tract , Acute On Chronic Liver Failure , Digestive Disease Week , Chronic Liver Failure , Disease Week , American Association , Liver Diseases , American Society , Gastrointestinal Endoscopy , Alimentary Tract , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Registration Document , Genfit Stock Exchange , Press Release , T Gnft Fr0004163111 ,

Genfit S.A. (NASDAQ:GNFT) Short Interest Up 7.8% in April

Genfit S.A. (NASDAQ:GNFT – Get Rating) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 100,500 shares, an increase of 7.8% from the March 31st total of 93,200 shares. Based on an average daily volume of 6,600 shares, the short-interest ratio is presently […] ....

United States , Envestnet Asset Management Inc , Citadel Advisors , Optiver Holding , Get Rating , Stock Down , Wealth Management , Asset Management , Genfit Daily , Nasdaq Gnft ,